Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Telomir Pharmaceuticals, Inc. Common Stock

TELO

Telomir Pharmaceuticals Inc is a preclinical-stage biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases rather than treating symptoms alone. The company's research targets fundamental cellular processes associated with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mitochondrial dysfunction, and telomere integrity. Telomir's investigational compound, Telomir-1 (Zn-Telomir), is a novel orally administered small molecule engineered to modulate intracellular metal balance particularly iron, copper, calcium, and zinc.

Last trade $0.4816
Day change +$0.0006 (+0.12%)
Day range $0.42 – $0.505
Volume 295,855
Market cap $35M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$35.36M
Price / earnings
—
Price / book
8.03×
Price / sales
—
EV / sales
—
EV / EBITDA
-5.44×

Profitability

Earnings per share
-$0.70
Return on assets
-1,111.59%
Return on equity
-1,171.34%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.02×
Current ratio
19.6×
Quick ratio
19.6×
Cash ratio
19.07×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$4.57M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for TELO, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$493.31K$1.32M$573.54K$838.47K$386.95K$5.03M$1.85M$2.64M
Research and development$251.89K$444.67K$467.8K$1.3M$759.53K$42.84K$337K$269.08K
Total operating expenses$745.2K$1.76M$1.04M$2.13M$1.15M$5.07M$2.19M$2.91M
Operating income-$745.2K-$1.76M-$1.04M-$2.13M-$1.15M-$5.07M-$2.19M-$2.91M
Interest expense-$1.91K-$3.03K-$1.26K$1.39K$0-$1.34K-$46$1
Income before taxes-$705.23K-$1.72M-$990.95K-$2.06M-$1.1M-$5.07M-$2.18M-$2.9M
Income taxes$0$0$0$0$0$0$0$0
Net income-$705.23K-$1.72M-$990.95K-$2.06M-$1.1M-$5.07M-$2.18M-$2.9M
Net income attributable to common shareholders-$705.23K-$47.84M-$990.95K-$2.06M-$1.1M-$5.07M-$2.18M-$2.9M
EBITDA-$745.2K-$1.76M-$1.04M-$2.13M-$1.15M-$5.07M-$2.19M-$2.91M
Basic earnings per share-$0.01-$0.79-$0.03-$0.06-$0.03-$0.17-$0.07-$0.10
Diluted earnings per share-$0.01-$0.79-$0.03-$0.06-$0.03-$0.17-$0.07-$0.10

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Telomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes

TAMPA, Fla., July 02, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps as a potential treatment for age-related conditions, today announced that the Company has been added as a member of the broad-market Russell 3000® and the Russell Microcap® Indexes, effective July 1, as part of the 2024 Russell indexes reconstitution.

GlobeNewswire Inc.

Telomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel

Drug Information Association (DIA) 2024 is the largest global, multidisciplinary event for the professionals involved in the discovery, development, and lifecycle management of pharmaceuticals, biotechnology, medical devices, and related products Drug Information Association (DIA) 2024 is the largest global, multidisciplinary event for the professionals involved in the discovery, development, and lifecycle management of pharmaceuticals, biotechnology, medical devices, and related products

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.